In this Healthed lecture, Dr Adam Nelson explains that weight loss should now be considered a therapeutic target in the same way we treat cholesterol and blood pressure when implementing secondary prevention after a heart attack for instance. Dr Nelson will also present evidence for the effectiveness of GLP-1 agonists in this space and how agents such as semaglutide can and should be included in clinical care according to international cardiology guidelines and even our own TGA recommendations.
See omnystudio.com/listener for privacy information.
